The robust U.S. IPO pipeline and recent pricing activity underpin trader sentiment for IPOs completing before year-end 2026. Multiple offerings priced in late September, including ADARx Pharmaceuticals’ upsized $446 million deal and SPAC listings such as Bluerock Acquisition II, while additional names like Oura and Accelevation Holdings Corp. are slated for September 30. Year-to-date volume has already exceeded prior cycles, propelled by SpaceX’s record June listing and sustained demand for AI-related and biotech issuers amid supportive equity valuations. Key near-term catalysts include further SEC filings, earnings releases, and any shifts in Treasury yields or Federal Reserve policy that could influence window timing through December.